Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
SourceJournal of the American Academy of Dermatology, 80, 1, (2019), pp. 70-+
Article / Letter to editor
Display more detailsDisplay less details
Journal of the American Academy of Dermatology
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.